Punicalin

CAS No. 65995-64-4

Punicalin( —— )

Catalog No. M20184 CAS No. 65995-64-4

Punicalin exerts anti-inflammatory antioxidative and anti-hepatotoxic activities it shows inhibitory activity on HIV-1 reverse transcriptase in a dose-dependent manner with an IC50 of 0.11 microg/ml (0.14 microM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 110 In Stock
10MG 178 In Stock
25MG 312 In Stock
50MG 464 In Stock
100MG 662 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Punicalin
  • Note
    Research use only, not for human use.
  • Brief Description
    Punicalin exerts anti-inflammatory antioxidative and anti-hepatotoxic activities it shows inhibitory activity on HIV-1 reverse transcriptase in a dose-dependent manner with an IC50 of 0.11 microg/ml (0.14 microM).
  • Description
    Punicalin exerts anti-inflammatory antioxidative and anti-hepatotoxic activities it shows inhibitory activity on HIV-1 reverse transcriptase in a dose-dependent manner with an IC50 of 0.11 microg/ml (0.14 microM).
  • In Vitro
    Western Blot Analysis Cell Line:J774A Concentration:0, 25, 50, 100 μM Incubation Time:The cells were pretreated with punicalin for one hour, followed by treated with Lipopolysaccharide (HY-D1056) for 5.5 h, ATP for half an hour, respectively.Result:Reduced the increased protein expression of NLRP3, ASC, Caspase-1 and GSDMD-N.Cell Cycle Analysis Cell Line:SH-SY5Y Concentration:10, 20 μM Incubation Time:24-72 h Result:Alleviated the rising of the G0/G1 phase ratio.Ameliorated OGD/R-mediated expression of cyclin B1, CDK1, p21 and phosphorylation of CDK1 at 20 μM.Cell Viability Assay Cell Line:J774A Concentration:0, 25, 50, 100 μM Incubation Time:24 h Result:Promoted cell viability and decreased the release of pro-inflammatory cytokines.
  • In Vivo
    Animal Model:Carrageenan (HY-125474)-induced Edema in rats Dosage:5 mg/kg Administration:s.c.Result:Showed significant anti-inflammatory effect against carrageenan induced paw edema at all time intervals, but decreased the effects.with larger dose.Animal Model:LPS (HY-D1056)-induced acute lung injury mice Dosage:10 mg/kg Administration:i.p.Result:Reduced the mortality and attenuated the severity of lung pathological injury.Ameliorated LPS (HY-D1056)-induced lung edema and vascular leakage.
  • Synonyms
    ——
  • Pathway
    Microbiology/Virology
  • Target
    HIV
  • Recptor
    HIV-1
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    65995-64-4
  • Formula Weight
    782.52
  • Molecular Formula
    C34H22O22
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?H2O : 50 mg/mL (63.90 mM)
  • SMILES
    OC1O[C@@H]2COC(=O)c3cc(O)c(O)c(O)c3-c3c(O)c(O)c4oc(=O)c5c(c(O)c(O)c6oc(=O)c3c4c56)-c3c(O)c(O)c(O)cc3C(=O)O[C@H]2[C@H](O)[C@H]1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Lin CC et al. Effects of punicalagin and punicalin on carrageenan-induced inflammation in rats.Am J Chin Med. 1999;27(3-4):371-6.
molnova catalog
related products
  • (Rac)-Telinavir

    (Rac)-Telinavir shows anti-HIV activity.

  • HIV-1 inhibitor 18A

    HIV-1 inhibitor 18A is a novel broad HIV-1 inhibitor that blocks envelope glycoprotein transitions critical for entry.

  • HIV-1 Rev 34-50

    HIV-1 Rev (34-50) is a 17-aa peptide derived from the Rev-responsive element (RRE)-binding domains of Rev in HIV-1, with anti-HIV-1 activity. HIV-1 Rev peptide is a one of the cell-penetrating peptides (CPPs) derived from HIV-1 Rev protein residue 34-50. It is a RNA binding peptideand has been used to deliver macromolecules into cells.